Quantcast
Last updated on April 21, 2014 at 1:20 EDT

German Technology Aims to Make Methadone Treatment More Safe and Efficient

February 17, 2012


CAPE CORAL, Fla., Feb. 17, 2012 /PRNewswire-iReach/ — Fidelitas Medical IT-Solutions, LP announced today the launch of their product DDS, a dispensing and documentation system for methadone treatment. Their mission, according to the company’s CEO, Andreas Kunz, is to increase the safety and efficiency of MMT (Methadone Maintenance Treatment) programs in North America. “We have seen that patients are sometimes given inaccurate doses of methadone due to cumbersome documentation procedures. The risk of embezzled methadone that ends up on the streets is also a continuous problem.” Mr. Kunz says that Fidelitas can solve these problems with an automated, tamper proof, documentation and dispensing system that safely manages and records every single mg of methadone – from the time when the methadone arrives at the clinic until the stock is empty. “Clinic owners, authorities, doctors and nurses can be sure to work with a reliable system in which every action is documented safely and accurately.” Fidelitas’ Vice President, Joakim Jörlander, says, “The fear of making a mistake that could have fatal consequences naturally creates a lot of stress. Our experience from all the fourteen countries we are presently working in tells us that nurses and other staff feel a lot more comfortable doing their job when the documentation and dispensing is interactive and automated.”

(Photo: http://photos.prnewswire.com/prnh/20120217/CG55934)

DDS is listed as a medical device with the U.S. Food and Drug Administration and the company behind it is registered as a manufacturer of medical devices in the U.S. as well as Europe. Fidelitas’ entry on the U.S. market has not gone unnoticed and they are currently in negotiations with established companies. “The high interest is much due to our unique integration of software and dispenser, and it also shows that MMT programs in North America have needs that are yet to be fulfilled”, says Fidelitas CEO, Andreas Kunz. “Our mission is to make substitution treatment more safe, more efficient and more transparent. I believe this will make us the best friend of patients, clinics and authorities.” Vice President Joakim Jörlander explains that, “this is not just another methadone pump. We are specialists in the complete field of substitution treatment, and this is what makes the DDS stand out. In addition, we are positive that it will save costs for patients, clinics, states, and the government.”

Fidelitas Medical IT-Solutions, LP is the subsidiary of the well known German company CompWare Medical GmbH, which is the worldwide leading manufacturer of self regulating IT-based solutions in the field of OST (opioid substitution treatment) medicine. CompWare Medical GmbH possesses extensive knowledge after 25 years of experience in this particular field and is working together with UN Organizations, the federal ministry of health and other high-ranking organizations, i.e. in India and Nepal. Over 25,000 patients are treated with DDS daily around the world. The biggest market is in Germany, where around 250 clinics and prisons are using DDS. In Germany alone, the system helps to save millions of euros in health insurances every year.

For more information about DDS and Fidelitas Medical IT-Solutions, LP, please visit www.fidelitas-solutions.com or their Facebook page.

Media Contact: Joakim Jorlander Fidelitas Medical IT-Solutions, LP, 239-673-5118, info@fidelitas-solutions.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Fidelitas Medical IT-Solutions, LP


Source: PR Newswire